Pulsed Field Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter Cohort Study

Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called pulsed field ablation (PFA) for patients who have a specific type of heart rhythm problem known as cavotricuspid isthmus dependent atrial flutter, which often occurs alongside atrial fibrillation. The goal of the study is to see how safe and effective PFA is for treating these heart issues. In this trial, 30 patients aged 18 to 80 who are scheduled for heart ablation procedures will be included. Participants will need to meet certain criteria, like not having severe coronary artery disease or a history of previous heart ablation procedures.

If you join the study, you will undergo a routine heart procedure guided by advanced technology. After the initial treatment, you will return for a follow-up appointment in three months to check how well the procedure worked and to ensure there is no damage to the coronary arteries. During this follow-up, doctors will assess your heart's electrical signals, and if necessary, further treatment can be done. This trial aims to provide valuable information about the long-term effects and safety of using PFA for this type of atrial flutter.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with atrial fibrillation who are clinically planned to undergo AF ablation and atrial flutter ablation per guideline recommendations
• Exclusion Criteria:
• • 1. \>80 years old or \<18 years old
• • 2. Known severe coronary artery disease
• • 3. Prior history of atrial flutter or atrial fibrillation ablation
• • 4. Refusal for remapping or coronary angiogram
• • 5. Contraindication for coronary angiogram
• • 6. Pregnancy
• • 7. Expected life expectancy \<1 year
• • 8. Inability to provide informed consent